CoChat

Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial

Ge, Zhen, Kan, Jing, Gao, Xiaofei, Raza, Afsar, Zhang, Jun-Jie, Mohydin, Bilal S, Gao, Fentang, Shao, Yibing, Wang, Yan, Zeng, Hesong, Li, Feng, Khan, Hamid Sharif, Mengal, Naeem, Cong, Hongliang, Wang, Mingliang, Chen, Lianglong, Wei, Yongyue, Chen, Feng, Stone, Gregg W, Chen, Shao-Liang, Li, Xiaobo, Ge, Zhen, Kan, Jing, Anjum, Muhammed, Ye, Fei, Gao, Xiaofei, Jalal, Anjum, Xie, Ping, Tao, Ling, Chen, Xiang, Khan, Hamid S, Javed, Asim, Shao, Yibin, Guo, Xiaomei, Li, Feng, Saghir, Tahir, Mengal, Naeem, Nie, Shaoping, Qu, Hong, Qian, Xuesong, Yang, Song, Chen, Jing, Gao, Dasheng, Liu, Lijun, Wang, Mingliang, Chen, Lianglong, Liu, Fan, Xu, Tan, Liu, Yinwu, Gill, Badar Ul Ahad, Yang, Qing, Guo, Nin, Wen, Shangyu, Cong, Hongliang, Hong, Lang, Sheiban, Imad, Raza, Afsar, Wei, Yongyue, Chen, Feng, Mintz, Gary S, Zhang, Jun-Jie, Stone, Gregg W, Chen, Shao-Liang · 2024 · The Lancet
Cited by 183

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

BACKGROUND Following percutaneous coronary intervention with stent placement to treat acute coronary syndromes, international clinical guidelines generally recommend dual antiplatelet therapy with aspirin plus a P2Y12 receptor inhibitor for 12 months to prevent myocardial infarction and stent thrombosis. However, data on single antiplatelet therapy with a potent P2Y12 inhibitor earlier than 12 months after percutaneous coronary intervention for patients with an acute coronary syndrome are scarce. The aim of this trial was to assess whether the use of ticagrelor alone, compared with ticagrelor plus aspirin, could reduce the incidence of clinically relevant bleeding events without an accompanying increase in major adverse cardiovascular or cerebrovascular events (MACCE). METHODS In this randomised, placebo-controlled, double-blind clinical trial, patients aged 18 years or older with an acute coronary syndrome who completed the IVUS-ACS study and who had no major ischaemic or bleeding events after 1-month treatment with dual antiplatelet therapy were randomly assigned to receive oral ticagrelor (90 mg twice daily) plus oral aspirin (100 mg once daily) or oral ticagrelor (90 mg twice daily) plus a matching oral placebo, beginning 1 month and ending at 12 months after percutaneous coronary intervention (11 months in total). Recruitment took place at 58 centres in China, Italy, Pakistan, and the UK. Patients were required to remain event-free for 1 month on dual antiplatelet therapy following percutaneous coronary intervention with contemporary drug-eluting stents. Randomisation was done using a web-based system, stratified by acute coronary syndrome type, diabetes, IVUS-ACS randomisation, and site, using dynamic minimisation. The primary superiority endpoint was clinically relevant bleeding (Bleeding Academic Research Consortium [known as BARC] types 2, 3, or 5). The primary non-inferiority endpoint was MACCE (defined as the composite of cardiac death, myocardial infarction, ischaemic stroke, definite stent thrombosis, or clinically driven target vessel revascularisation), with an expected event rate of 6·2% in the ticagrelor plus aspirin group and an absolute non-inferiority margin of 2·5 percentage points between 1 month and 12 months after percutaneous coronary intervention. The two co-primary endpoints were tested sequentially; the primary superiority endpoint had to be met for hypothesis testing of the MACCE outcome to proceed. All principal analyses were assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03971500, and is completed. FINDINGS Between Sept 21, 2019, and Oct 27, 2022, 3400 (97·0%) of the 3505 participants in the IVUS-ACS study were randomly assigned (1700 patients to ticagrelor plus aspirin and 1700 patients to ticagrelor plus placebo). 12-month follow-up was completed by 3399 (>99·9%) patients. Between month 1 and month 12 after percutaneous coronary intervention, clinically relevant bleeding occurred in 35 patients (2·1%) in the ticagrelor plus placebo group and in 78 patients (4·6%) in the ticagrelor plus aspirin group (hazard ratio [HR] 0·45 [95% CI 0·30 to 0·66]; p<0·0001). MACCE occurred in 61 patients (3·6%) in the ticagrelor plus placebo group and in 63 patients (3·7%) in the ticagrelor plus aspirin group (absolute difference -0·1% [95% CI -1·4% to 1·2%]; HR 0·98 [95% CI 0·69 to 1·39]; pnon-inferiority<0·0001, psuperiority=0·89). INTERPRETATION In patients with an acute coronary syndrome who had percutaneous coronary intervention with contemporary drug-eluting stents and remained event-free for 1 month on dual antiplatelet therapy, treatment with ticagrelor alone between month 1 and month 12 after the intervention resulted in a lower rate of clinically relevant bleeding and a similar rate of MACCE compared with ticagrelor plus aspirin. Along with the results from previous studies, these findings show that most patients in this population can benefit from superior clinical outcomes with aspirin discontinuation and maintenance on ticagrelor monotherapy after 1 month of dual antiplatelet therapy. FUNDING The Chinese Society of Cardiology, the National Natural Scientific Foundation of China, and the Jiangsu Provincial & Nanjing Municipal Clinical Trial Project. TRANSLATION For the Mandarin translation of the abstract see Supplementary Materials section.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)00473-2

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 183

Metadata

Authors
Ge, Z., Kan, J., Gao, X., Raza, A., Zhang, J.-J., Mohydin, B. S., Gao, F., Shao, Y., Wang, Y., Zeng, H., Li, F., Khan, H. S., Mengal, N., Cong, H., Wang, M., Chen, L., Wei, Y., Chen, F., Stone, G. W., Chen, S.-L., Li, X., Ge, Z., Kan, J., Anjum, M., Ye, F., Gao, X., Jalal, A., Xie, P., Tao, L., Chen, X., Khan, H. S., Javed, A., Shao, Y., Guo, X., Li, F., Saghir, T., Mengal, N., Nie, S., Qu, H., Qian, X., Yang, S., Chen, J., Gao, D., Liu, L., Wang, M., Chen, L., Liu, F., Xu, T., Liu, Y., Gill, B. U. A., Yang, Q., Guo, N., Wen, S., Cong, H., Hong, L., Sheiban, I., Raza, A., Wei, Y., Chen, F., Mintz, G. S., Zhang, J.-J., Stone, G. W., & Chen, S.-L.
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-05
Volume
403
Issue
10439
Pages
1866-1878
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4394061715
Cited by
183
References
5
FWCI
49.16
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. https://app.cochat.ai/papers/10.1016/s0140-6736(24)00473-2
The paper
Ge, Z., Kan, J., Gao, X., Raza, A., Zhang, J.-J., Mohydin, B. S., Gao, F., Shao, Y., Wang, Y., Zeng, H., Li, F., Khan, H. S., Mengal, N., Cong, H., Wang, M., Chen, L., Wei, Y., Chen, F., Stone, G. W., . . . Chen, S.-L. (2024). Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. The Lancet. https://doi.org/10.1016/s0140-6736(24)00473-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.